Human Papillomavirus Protein E6 (E6) - Pipeline Review, H1 2018

  • ID: 4518489
  • Drug Pipelines
  • 81 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abion Inc
  • BioNTech AG
  • Etubics Corp
  • Genexine Inc
  • Hookipa Biotech AG
  • MedImmune LLC
  • MORE
Human Papillomavirus Protein E6 (E6) - Pipeline Review, H1 2018

Summary:

Human Papillomavirus Protein E6 (E6) - The Human Papillomavirus (HPV) E6 protein is one of oncoproteins encoded by the virus. It is a 151 amino-acid peptide. It plays a major role in the induction and maintenance of cellular transformation. It acts mainly as an oncoprotein by stimulating the destruction of many host cell key regulatory proteins.

The complex E6/E6P targets several other substrates to degradation via the proteasome including host NFX1-91. The resulting increased expression of hTERT prevents the shortening of telomere length leading to cell immortalization.

Human Papillomavirus Protein E6 (E6) pipeline Target constitutes close to 27 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 3 and 11 respectively.

Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 4 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health and Infectious Disease which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Cancer, Anal Cancer, Glioblastoma Multiforme (GBM), Human Papillomavirus Infections, Lung Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Oropharyngeal Cancer, Penile Cancer, Vaginal Cancer and Vulvar Cancer.

The latest report Human Papillomavirus Protein E6 (E6) - Pipeline Review, H1 2018, outlays comprehensive information on the Human Papillomavirus Protein E6 (E6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E6 (E6)
  • The report reviews Human Papillomavirus Protein E6 (E6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Human Papillomavirus Protein E6 (E6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Human Papillomavirus Protein E6 (E6) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E6 (E6)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E6 (E6) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abion Inc
  • BioNTech AG
  • Etubics Corp
  • Genexine Inc
  • Hookipa Biotech AG
  • MedImmune LLC
  • MORE
Introduction

Report Coverage

Human Papillomavirus Protein E6 (E6) - Overview

Human Papillomavirus Protein E6 (E6) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Human Papillomavirus Protein E6 (E6) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Human Papillomavirus Protein E6 (E6) - Companies Involved in Therapeutics Development

Abion Inc

BioNTech AG

Cancer Research Technology Ltd

Etubics Corp

Genexine Inc

Hookipa Biotech AG

Inovio Pharmaceuticals Inc

MedImmune LLC

Rottapharm Biotech Srl

Selecta Biosciences Inc

Touchlight Genetics Ltd

Transgene SA

Human Papillomavirus Protein E6 (E6) - Drug Profiles

ABN-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Inhibit E6 for HPV Associated Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BVAC-C - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-041 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GX-188E - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus [serotype 16] vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus [serotypes 16] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-3106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-0457 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit E6 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVX-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SEL-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit E6 for Human Papillomavirus Associated Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TA-CIN - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-4001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tricurin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for HPV Associated Cervical Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target E6 and E7 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VGX-3100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vvax-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Human Papillomavirus Protein E6 (E6) - Dormant Products

Human Papillomavirus Protein E6 (E6) - Discontinued Products

Human Papillomavirus Protein E6 (E6) - Product Development Milestones

Featured News & Press Releases

Jan 08, 2018: Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase

Nov 29, 2017: Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy

Nov 27, 2017: Inovio Pharmaceuticals Provides Update on Cancer Drug Candidate INO-3

Nov 10, 2017: Inovio Pharmaceuticals Presents data on MEDI0457 at Society for Immunotherapy of Cancer Conference

Sep 19, 2017: Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers

Jun 19, 2017: Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA, for the Treatment of HPV-Induced Cervical Cancer

Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer

May 10, 2017: Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer

Apr 24, 2017: Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers

Mar 06, 2017: Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech

Nov 14, 2016: Inovios Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer

Oct 24, 2016: Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed

Oct 17, 2016: Hookipa Secures EUR 4.16 Million Additional Grant Support from the Austrian Research Promotion Agency (FFG) to Develop Arenavirus Vector-Based Cancer Immunotherapies

Oct 12, 2016: Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio

Jun 21, 2016: Genexine Presents Interim Clinical Data of GX-188E at EUROGIN 2

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Abion Inc, H1 2018

Pipeline by BioNTech AG, H1 2018

Pipeline by Cancer Research Technology Ltd, H1 2018

Pipeline by Etubics Corp, H1 2018

Pipeline by Genexine Inc, H1 2018

Pipeline by Hookipa Biotech AG, H1 2018

Pipeline by Inovio Pharmaceuticals Inc, H1 2018

Pipeline by MedImmune LLC, H1 2018

Pipeline by Rottapharm Biotech Srl, H1 2018

Pipeline by Selecta Biosciences Inc, H1 2018

Pipeline by Touchlight Genetics Ltd, H1 2018

Pipeline by Transgene SA, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abion Inc
  • BioNTech AG
  • Cancer Research Technology Ltd
  • Etubics Corp
  • Genexine Inc
  • Hookipa Biotech AG
  • Inovio Pharmaceuticals Inc
  • MedImmune LLC
  • Rottapharm Biotech Srl
  • Selecta Biosciences Inc
  • Touchlight Genetics Ltd
  • Transgene SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll